| Chapter title |
Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
|
|---|---|
| Chapter number | 8 |
| Book title |
Urothelial Carcinoma
|
| Published in |
Methods in molecular biology, January 2023
|
| DOI | 10.1007/978-1-0716-3291-8_8 |
| Pubmed ID | |
| Book ISBNs |
978-1-07-163290-1, 978-1-07-163291-8
|
| Authors |
Park, Youngrok, Lelo, Alana, Harris, Brent, Berry, Deborah L, Chaldekas, Krysta, Kim, Jung-Sik, Waldman, Todd, Berry, Deborah L. |
| Abstract |
Bladder cancer is the fifth most common cancer in the United States. Most bladder cancers are early-stage lesions confined to the mucosa or submucosa and are therefore classified as non-muscle-invasive bladder cancer (NMIBC). A minority of tumors are diagnosed after they have invaded the underlying detrusor muscle and are classified as muscle-invasive bladder cancer (MIBC). Mutational inactivation of the STAG2 tumor suppressor gene is common in bladder cancer, and we and others have recently demonstrated that STAG2 mutation status can be used as an independent prognostic biomarker to predict whether NMIBC will recur and/or progress to MIBC. Here we describe an immunohistochemistry-based assay for identifying the STAG2 mutational status of bladder tumors. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 2 | 67% |
| Unknown | 1 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 1 | 33% |
| Agricultural and Biological Sciences | 1 | 33% |
| Unknown | 1 | 33% |